Presenilin-directed inhibitors of γ-secretase trigger caspase 3 activation in presenilin-expressing and presenilin-deficient cells

Journal of Neurochemistry

Volumn 90, Issue 4, 2004, Pages 800-806

  Alves Da Costa, Cristine ^a   Ayral, Erwan ^b   Hernandez, Jean François ^b   St George Hyslop, Peter ^c   Checler, Frédéric ^a,d  

^a CNRS   (France)

^b UNIVERSITÉ DE MONTPELLIER   (France)

^c Tanz Neurosciences Building ^*  (Canada)

^d INSTITUT DE PHARMACOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

secretase; Caspase 3; Inhibitors; Presenilins; Presenilins knockout

Indexed keywords

AMYLOID BETA PROTEIN; CALPAIN; CASPASE 3; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; PRESENILIN 1;

ALZHEIMER DISEASE; ANIMAL CELL; APOPTOSIS; ARTICLE; BLASTOCYST; CELL FUNCTION; CONTROLLED STUDY; DEGENERATIVE DISEASE; ENZYME ACTIVATION; ENZYME INHIBITION; FIBROBLAST; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; WILD TYPE;

AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ASPARTIC ENDOPEPTIDASES; BLASTOCYST; CALPAIN; CASPASE 3; CASPASES; CELL SURVIVAL; CELLS, CULTURED; ENDOPEPTIDASES; ENZYME ACTIVATION; ENZYME INHIBITORS; FIBROBLASTS; MEMBRANE PROTEINS; MICE; PRESENILIN-1; PRESENILIN-2;

ANIMALIA;

EID: 4143066847     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2004.02512.x     Document Type: Article

References (57)

1. Alves da Costa C., Paitel E., Mattson M. P., Amson R., Telerman A., Ancolio K. and Checler F. (2002) Wild-type and mutated presenilin-2 trigger p53-dependent apoptosis and down-regulate presenilin-1 expression in HEK293 human cells and in murine neurons. Proc. Natl Acad. Sci. USA 99, 4043-4048.
2. Araki W. (2000) Presenilins and cell death. Curr. Topics Biochem. Res. 3, 157-162.
3. Armogida M., Petit A., Vincent B., Scarzello S., Alves da Costa C. and Checler F. (2001) Endogenous β-amyloid production in presenilin-deficient embryonic mouse fibroblasts. Nat. Cell. Biol. 3, 1030-1033.
4. Beher D., Wrigley J. D. J., Nadin A., Evin G. and Masters C. L., Harrison T., Castro J. L. and Shearman M. S. (2001) Pharmacological knock-down of the presenilin 1 heterodimer by a novel γ-secretase inhibitor-implications for presenilin biology. J. Biol. Chem. 276, 45394-45402.
5. Bizat N., Hermel J.-M., Humbert S., Jacquart C., Créminon C., Escartin C., Saudou F., Krajewski S., Hantraye P. and Brouillet E. (2003) In vivo calpain/caspase cross-talk during 3-nitropropionic acid-induced striatal degeneration. Implication of a calpain-mediated cleavage of active caspase-3. J. Biol. Chem. 278, 43245-43253.
6. Checler F. (1995) Processing of the β-amyloid precursor protein and its regulation in Alzheimer's disease. J. Neurochem. 65, 1431-1444.
7. Checler F. (1999) Presenilins: multifunctional proteins involved in Alzheimer's disease pathology. Iubmb LIFE 48, 33-39.
8. Checler F. (2001) The multiple paradoxes of presenilins. J. Neurochem. 76, 1621-1627.
9. Citron M. (2001) Human β-secretase and Alzheimer's disease. Expert opin. Ther Targets 5, 341-348.
10. De Strooper B., Annaert W., Cupers P. et al. (1999) A presenilin-1-dependent γ-secretase-like protease mediates release of Notch intracellular domain. Nature 398, 518-522.
11. Dingwall C. (2001) Spotlight on BACE: The secretases as targets for treatment in Alzheimer disease. J. Clin. Invest. 108, 1243-1246.
12. Dovey H. F., John V., Anderson J. P. et al. (2001) Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J. Neurochem. 76, 173-181.
13. Esler W. P., Das C., Campbell W. A. et al. (2002) Amyloid-lowering isocoumarins are not direct inhibitors of γ-secretase. Nat. Cell. Biol. 4, E110-E111.
14. Esler W. P., Kimberly W. T., Ostaszewski B., Diehl T. S., Moore C. L., Tsai J.-Y., Rahmati T., Xia W., Selkoe D. J. and Wolfe M. S. (2000) Transition-state analogue inhibitors of γ-secretase bind directly to presenilin-1. Nat. Cell. Biol. 2, 428-434.
15. Francis R., McGrath G., Zhang J. et al. (2002) aph-1 and pen-2 are required for notch pathway signaling, γ-secretase cleavage of βAPP, and presenilin protein accumulation. Dev. Cell. 3, 85-97.
16. Haass C. (1997) Presenilins: genes for life and death. Neuron 18, 687-690.
17. Hardy J. A. and Higgins G. A. (1992) Alzheimer's disease: the amyloid cascade hypothesis. Science 256, 184-185.
18. Hardy J. and Selkoe D. J. (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356.
19. Herreman A., Semeels L., Annaert W., Collen D., Schoonjans L. and De Strooper B. (2000) Total inactivation of γ-secretase activity in presenilin-deficient embryonic stem cells. Nat. Cell. Biol. 2, 461-462.
20. John V., Beck J. P., Bienkowski M. J., Sinha S. and Heinrickson R. L. (2003) Human β-secretase (BACE) and BACE inhibitors. J. Med. Chem. 46, 4625-4630.
21. Josien H. (2002) Recent advances in the development of γ-secretase inhibitors. Curr. Op. Drug Disc. Dev. 5, 513-525.
22. Kimberly W. T., Esler W. P. YeW., Ostaszewski B. L., Gao J., Diehl T., Selkoe D. J. and Wolfe M. S. (2003b) Notch and the amyloid precursor protein are cleaved by similar g-secretase (s). Biochemistry 42, 137-144.
23. Kimberly W. T., LaVoie M. J., Ostaszewski B. L. Ye, W. Wolfe M. S. and Selkoe D. J. (2003a) γ-Secretase is a membrane protein complex comprised of presenilin, nicastrin, aph-1 and pen-2. Proc. Natl Acad. Sci. USA 100, 6382-6387.
24. Kopan R. and Goate A. (2000) A common enzyme connects Notch signaling and Alzheimer's disease. Genes Dev. 14, 2799-2806.
25. Kopan R. Schroeter E. H. Weintraub H. and Nye J. S. (1996) Signal transduction by activated mNotch: importance of proteolytic processing and its regulation by the extracellular domain. Proc. Natl Acad. Sci. USA 93, 1683-1688.
26. Kubbutat M. H. G. and Vousden K. H. (1997) Proteolytic cleavage of human p53 by calpain: a potential regulator of protein stability. Mol. Cell. Biol. 17, 460-468.
27. Lai E. C. (2002) Notch cleavage: nicastrin help presenilin make the final cut. Curr. Biol. 12, R200-R202.
28. Lai M.-T., Chen E., Crouthamel M.-C. et al. (2003) Presenilin-1 and presenilin-2 exhibit distinct yet overlapping γ-secretase activities. J. Biol. Chem. 278, 22475-22481.
29. Li Y.-M., Lai M.-T., Huang Q. et al. (2000) Photoactivated γ-secretase inhibitors directed to the active site covalently label presenilin 1. Nature 405, 689-694.
30. Marambaud P., Shioi J., Serban G. et al. (2002) A presenilin-1/γ- secretase cleavage releases the E-cadherin intracellular domain and regulates disassembly of adherens junctions. EMBO J. 21, 1948-1956.
31. Mattson M. P., Guo Q., Furukawa K. and Pedersen W. A. (1998) Presenilins, the endoplasmic reticulum, and neuronal apoptosis in Alzheimer's disease. J. Neurochem. 70, 1-14.
32. Neumar R. W., Xu Y. A., Gada H., Guttmann R. P. and Siman R. (2003) Crosstalk between calpain and caspase proteolytic systems during neuronal apoptosis. J. Biol. Chem. 278, 14162-14167.
33. Ni C.-Y., Murphy M. P., Golde T. E. and Carpenter G. (2001) γ-secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science 294, 2179-2181.
34. Octave J. N. (1995) The amyloid peptide and its precursor in Alzheimer's disease. Rev. Neurosci. 6, 287-316.
35. Olson R. E., Copeland R. A. and Seiffert D. (2001) Progress towards testing the amyloid hypothesis: inhibitors of APP processing. Curr. Op. Drug Disc. Dev. 4, 390-401.
36. Petit A., Bihel F., Alves da Costa C., Pourquié O., Kraus J. L. and Checler F. (2001) New protease inhibitors prevent γ-secretase-mediated Aβ40/42 production without affecting Notch cleavage. Nat. Cell. Biol. 3, 507-511.
37. Petit A., Pasini A., Alves da Costa C. et al. (2003) JLK isocoumarin inhibitors: selective γ-secretase inhibitors that do not interfere with Notch pathway in Vitro and in Vivo. J. Neurosci. Res. 74, 370-377.
38. Plant L. D., Boyle J. P., Smith I. F., Peers C. and Pearson H. A. (2003) The production of amyloid β peptide is a critical requirement for the viability of central neurons. J. Neurosci. 23, 5531-5535.
39. Seiffert D., Bradley J. D., Rominger C. M. et al. (2000) Presenilin-1 and -2 are molecular targets for γ-secretase inhibitors. J. Biol. Chem. 275, 34086-34091.
40. Selkoe D. J. (2001) Presenilin, Notch, and the genesis and treatment of Alzheimer's disease. Proc. Natl Acad. Sci. USA 98, 11039-11041.
41. Shearman M. S., Beher D., Clarke E. E., Lewis H. D., Harrison T., Hunt P., Nadin A., Smith A. L., Stevenson G. and Castro J. L. (2000) L-685,458, an aspartyl protease transition state mimic, is a potent inhibitor of amyloid β-protein precursor γ-secretase activity. Biochemistry 39, 8698-8704.
42. Sisodia S. S., Annaert W., Kim S.-H. and de Strooper B. (2001) γ-Secretase: never more enigmatic. Trends Neurosci. 24, S2-S6.
43. Sisodia S. S. and St George-Hyslop P. (2002) γ-Secretase, notch, Aβ and Alzheimer's disease: where do the presenilins fit in? Nat. Rev. Neurosci. 3, 281-290.
44. Small D. (2001) The role of presenilins in γ-secretase activity: catalyst or cofactor? J. Neurochem. 76, 1612-1614.
45. Steiner H. and Haass C. (2000) Intramembrane proteolysis by presenilins. Nat. Rev. 1, 217-224.
46. Suh Y.-H. and Checler F. (2002) Amyloid precursor protein, presenilins and α-synuclein: Molecular pathogenesis and pharmacological applications in Alzheimers' disease. Pharmacol. Rev. 54, 469-525.
47. Takasugi N., Tomita T., Hayashi I., Tsuruoka M., Niimura M., Takahashi Y., Thinakaran G. and Iwatsubo T. (2003) The role of presenilin cofactors in the γ-secretase complex. Nature 422, 438-441.
48. Thinakaran G. (1999) The role of presenilins in Alzheimers' disease. J. Clin. Invest. 104, 1321-1327.
49. Vassar R. (2001) The β-secretase, BACE. J. Mol. Neurosci. 17, 157-170.
50. Wang K. K. W., Posmantur R., Nadimpalli R., Nath R., Mohan P., Nixon R. A., Talanian R. V., Keegan M., Herzog L. and Allen H. (1998) Caspase-mediated fragmentation of calpain inhibitor protein calpastatin during apoptosis. Arch. Biochem. Biophys. 356, 187-196.
51. Wolfe M. S. (2001a) Presenilins and γ-secretase: structure meets function. J. Neurochem. 76, 1615-1620.
52. Wolfe M. S. (2001b) Secretase targets for Alzheimer's disease: identification and therapeutic potential. J. Med. Chem. 44, 2039-2060.
53. Wolfe M. S., Citron M., Diehl T. S., Xia W., Donkor I. O. and Selkoe D. J. (1998) A substrate-based difluoro ketone selectively inhibits Alzheimer's γ-secretase actiivty. J. Med. Chem. 41, 6-9.
54. Wong G., Manfra D., Poulet F. M. et al. (2004) Chronic treatment with the γ-secretase inhibitor LY-411,575 inhibits Aβ production and alters lymphopoiesis and intestinal cell differentiation. J. Biol. Chem. 279, 12876-12882.
55. Yu, G., Nishimura M., Arawaka S. et al. (2000) Nicastrin modulates presenilin-mediated notch/glp1 signal transduction and βAPP processing. Nature 407, 48-54.
56. Zhang Z., Nadeau P., Song W., Donoviel D., Yuan M., Bernstein A. and Yankner B. A. (2000) Presenilins are required for γ-secretase cleavage of βAPP and transmembrane cleavage of Notch. Nat. Cell. Biol. 2, 463-465.
57. Zou K., Kim D., Kakio A. et al. (2003) Amyloid β-protein (Aβ) 1-40 protects neurons from damage induced by Aβ1-42 in culture and in rat brain. J. Neurochem. 87, 609-619.